Beyond Cancer Announces Approval by the Israeli Ministry of Health to Conduct a Phase 1b Clinical Trial Utilizing Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) in Combination with Anti-PD-1 Therapy
Portfolio Pulse from
Beyond Cancer, Ltd. has received approval from the Israeli Ministry of Health to conduct a Phase 1b clinical trial using Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) in combination with anti-PD-1 therapy for solid tumors. The trial will start patient screening in early 2025 at four sites in Israel.
December 03, 2024 | 9:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Beyond Cancer, potentially linked to XAIR, has received approval for a Phase 1b trial in Israel using LV UNO with anti-PD-1 therapy. This regulatory approval could positively impact XAIR if they are involved.
The approval of a clinical trial involving a novel therapy could boost investor confidence in companies associated with the technology. If XAIR is involved with Beyond Cancer, this news could lead to a positive short-term impact on its stock price.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50